Abstract: The present invention provides a stable oral pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salts thereof and at least one alkalizing agent selected from the group consisting of sodium hydroxide, sodium carbonate and sodium bicarbonate, and an aqueous solution or an aqueous dispersion of the pitavastatin containing preparation having a pH of more than 8 and 10 or less; and a method for producing the pitavastatin containing preparation.
Abstract: The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.
Type:
Application
Filed:
November 16, 2018
Publication date:
March 7, 2019
Applicant:
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: A method of selectively inhibiting the overexpression of mPGES-1 in a subject in need thereof includes a step of administering an effective amount of a selective mPGES-1 inhibitor or a salt thereof to the subject. A method of treating a subject suffering from a disease associated with an overexpression of mPGES-1 and having a risk of cardiovascular event includes the step of administering an effective amount of a selective mPGES-1 inhibitor to the subject.
Abstract: The present invention belongs to the field of pharmaceutical formulation, and particularly relates to an aripiprazole injectable suspension formulation having prolonged shelf life, and methods of using the formulation in treating schizophrenia and related diseases. In another aspect, the present invention also relates to a method of prolonging shelf life of an aripiprazole injectable suspension formulation.
Type:
Application
Filed:
March 16, 2016
Publication date:
March 7, 2019
Applicant:
NORATECH PHARMACEUTICALS, INC.
Inventors:
Yunzhe SUN, Qi PENG, Cheng-Gang LIN, Li GUI, Zhihui LIU, Fei LIU
Abstract: Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.
Type:
Application
Filed:
August 1, 2018
Publication date:
March 7, 2019
Applicant:
IGNYTA, INC.
Inventors:
Zachary Dolph HORNBY, Gang LI, David Wesley ANDERSON, Garrett M. BRODEUR, Radhika IYER
Abstract: Methods of using the antipsychotic drug aripiprazole in treating a neurodegenerative disease such as Machado-Joseph disease/Spinocerebellar ataxia type 3 (MJD/SCA3) are disclosed. The methods comprise administering aripiprazole in an amount effect to decrease protein aggregates in the central nervous system and intracellular forms of pathogenic proteins such as mutant ataxin-3.
Type:
Application
Filed:
March 10, 2017
Publication date:
March 7, 2019
Inventors:
Maria Do Carmo Pereira Da Costa, Henry L. Paulson
Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
Type:
Application
Filed:
November 5, 2018
Publication date:
March 7, 2019
Applicant:
Sun Pharma Advanced Research Company Limited
Abstract: Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed.
Type:
Application
Filed:
July 6, 2018
Publication date:
March 7, 2019
Inventors:
Eduardo M. Sotomayor, Alejandro V. Villagra
Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
Type:
Application
Filed:
August 28, 2018
Publication date:
March 7, 2019
Inventors:
Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
Abstract: The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof.
Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
Abstract: The present invention relates to a formulation of ticagrelor or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to an improved formulation of ticagrelor or a pharmaceutically acceptable salt thereof, which is administered once a day. In the present invention, the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL within 2 hours; and the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL at 12 hours after administration; and the maximum plasma concentration (Cmax) of ticagrelor or a pharmaceutically acceptable salt thereof in a subject is between about 0.2 ?g/mL and about 0.8 ?g/mL. The formulation of the present invention can reduce the frequency of administration, thereby improving patient compliance and reducing the risk of myocardial infarction or stroke induced by acute thrombosis which is caused by missed administration of ticagrelor.
Abstract: Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof. Also disclosed are methods of inhibiting growth and proliferation of cancer cells in vitro or in vivo, which include contacting the cells with an amount of the compound of formula (I) effective to inhibit the growth or proliferation of the cancer cells. Further disclosed are methods of inhibiting tumor growth, which include contacting the tumor with an amount of the compound of formula (I) effective to inhibit the growth of the tumor.
Type:
Application
Filed:
November 2, 2018
Publication date:
March 7, 2019
Inventors:
Sanjeeva P. Reddy, Sandeep Gupta, Roger Astbury Smith
Abstract: The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1?) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1? inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.
Type:
Application
Filed:
November 4, 2016
Publication date:
March 7, 2019
Inventors:
Changchun Deng, Shi-Xian Deng, Donald W. Landry, Mark Lipstein, Michael Mangone, Owen O'Connor, Xavier O. Jirau Serrano, Luigi Scotto, Xiaoming Xu
Abstract: Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a ?2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
Type:
Application
Filed:
November 1, 2018
Publication date:
March 7, 2019
Applicant:
G1 Therapeutics, Inc.
Inventors:
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Abstract: Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.
Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
Type:
Application
Filed:
November 2, 2018
Publication date:
March 7, 2019
Inventors:
Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
Abstract: The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.
Type:
Application
Filed:
November 7, 2016
Publication date:
March 7, 2019
Inventors:
Heike KEILHACK, Sarah K. KNUTSON, Nigel WATERS
Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
Type:
Application
Filed:
August 3, 2018
Publication date:
March 7, 2019
Inventors:
Daniel CHU, Bing WANG, Ying FENG, Yuqiao SHEN, Leonard E. POST
Abstract: Disclosed are methods and compositions for treating pediatric embryonal tumors. The methods and compositions utilize or include an inhibitor of polo-like kinase 4 (PLK4) for treating pediatric embryonal tumors.
Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
Type:
Application
Filed:
October 29, 2018
Publication date:
March 7, 2019
Inventors:
Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
Abstract: Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.
Abstract: Tricyclic compounds, including tricyclic iminodibenzylic and tricyclic iminostilbene compounds, are identified as therapeutic agents for inhibition of delta-5-desaturase (D5D) and for treating or preventing cancer and precancerous conditions, as well as autoimmune and inflammatory conditions. Pharmaceutical compositions and dietary supplements are provided, as are methods of administration and treatment.
Type:
Application
Filed:
August 31, 2018
Publication date:
March 7, 2019
Applicant:
NDSU Research Foundation
Inventors:
Yue (Steven) Qian, Pinjing Zhao, Changhui Yan
Abstract: The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.
Type:
Application
Filed:
November 6, 2018
Publication date:
March 7, 2019
Inventors:
Mao YIN, Joshua D. THOMAS, Aleksandr V. YURKOVETSKIY, Patrick R. CONLON, Bingfan DU, Eugene W. KELLEHER, Timothy B. LOWINGER, Shuyi TANG
Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of 4.5% by mass to 10.0% by mass with respect to the entire mass of the pharmaceutical composition, at least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol in an amount of 8% by mass to 23% by mass with respect to the entire mass of the pharmaceutical composition, benzyl alcohol in an amount of 5% by mass to 24% by mass with respect to the entire mass of the pharmaceutical composition, benzyl benzoate in an amount of 8% by mass to 19% by mass with respect to the entire mass of the pharmaceutical composition, and castor oil, and in which a content of ethanol is less than 1% by mass with respect to the entire mass of the pharmaceutical composition, and a content of benzoic acid is less than 1% by mass with respect to the entire mass of the pharmaceutical composition.
Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Type:
Application
Filed:
November 7, 2018
Publication date:
March 7, 2019
Inventors:
Robert E. DUDLEY, Panayiotis P. CONSTANTINIDES
Abstract: This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.
Type:
Application
Filed:
September 7, 2018
Publication date:
March 7, 2019
Inventors:
JULIA AMADIO, ANNETTE SHADIACK, PETER H.R. PERSICANER, RICHARD WINNEKER, JASON LEGASSIE, THORSTEINN THORSTEINSSON, AJAY GHANTA
Abstract: Compositions comprising at least two of a corticosteroid, a non-steroidal anti- inflammatory drug (NSAID), and an antibiotic find use in treating or preventing eye conditions in subjects in need thereof. Methods of treatment or prevention of eye conditions comprise administering an effective amount of the disclosed compositions to the affected eye(s). Methods of preparing a composition comprising an NSAID, a corticosteroid, and an antibiotic comprise separately complexing the NSAID and antibiotic with cyclodextrin.
Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.
Abstract: Methods of inhibiting bacterial conjugation, bacterial horizontal gene transfer or bacterial growth are disclosed. The methods comprise contacting bacteria with an effective amount of a bile acid or a bile salt, wherein the effective amount does not affect viability of the bacteria. A method of increasing susceptibility of bacteria to antibiotic treatment is also disclosed as well as methods of decontaminating a farm animal housing or a medical surface and methods of treating water. Also disclosed are compositions effective in inhibiting bacterial conjugation, bacterial horizontal gene transfer and bacterial growth.
Abstract: Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID.
Abstract: The field of the present invention is that of fosfomycin formulations for parenteral administration, in particular for intravenous administration. Formulations of the prior art provide fosfomycin as a powder to be diluted directly prior to the administration. The aim of the invention is to provide a fosfomycin formulation for parenteral administration which is easier to produce and administer or which lowers the risk of puncture injuries for healthcare professionals and the health risks for the patients (for example due to contamination or incorrect dosages) by preventing additional processing steps. During the course of the invention, it was surprisingly shown that fosfomycin is much more stable in an aqueous solution than what is commonly assumed.
Type:
Application
Filed:
March 16, 2017
Publication date:
March 7, 2019
Inventors:
Apostolos Georgopoulos, Albert Schifer, Wolfgang Rous
Abstract: Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.
Type:
Application
Filed:
November 5, 2018
Publication date:
March 7, 2019
Inventors:
Inge Bruheim, Mikko Griinari, Sebastiano Banno, Per Christian Saebo, Erik Fuglseth
Abstract: [Problem] To provide a substance and method that are capable of effectively inducing proliferation of Faecalibacterium, thereby contributing to the prevention and treatment of diseases such as intestinal inflammation. [Solution] A proliferative agent for Faecalibacterium, comprising 1-kestose as an active ingredient. In accordance with the present invention, proliferation of Faecalibacterium can be effectively induced both in vitro and in vivo. In particular, it is possible to simply and effectively increase in vivo proliferation of Faecalibacterium in humans and animals, with almost no concerns regarding side effects or safety. It is also possible to prevent or treat intestinal inflammation by increasing in vivo proliferation of Faecalibacterium in humans and animals.
Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of at least one of a flavonoid and a chlorogenic acid that are natural extracts of Parrotia persica, or their derivatives, analogues, or homologs. Compounds based upon these natural extracts have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.
Type:
Application
Filed:
September 5, 2018
Publication date:
March 7, 2019
Inventors:
EHSAN JABBARZADEH, SARA ESLAMBOLCHI MOGHADAM
Abstract: The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.
Type:
Application
Filed:
August 2, 2018
Publication date:
March 7, 2019
Inventors:
Michael Sekar, Su Il Yum, Felix Theeuwes, William Van Osdol
Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).
Type:
Application
Filed:
March 10, 2017
Publication date:
March 7, 2019
Applicants:
KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, DAIKIN INDUSTRIES, LTD.
Abstract: Provided are uses of an adenosine derivative, shown in formula (I), in preparing pharmaceuticals for the prevention or/and treatment of hyperlipidemia-associated monocytosis, and for the prevention or/and treatment of atherosclerosis. The prevention or/and treatment of atherosclerosis refers to the prevention or/and treatment of atherosclerosis-associated inflammatory monocytosis.
Abstract: Embodiments of the present invention disclose a composition comprising nicotinamide adenine dinucleotide (NAD+) and optionally a nonsteroidal anti-inflammatory drug (NSAID), wherein the NAD+ is in an amount effective for a condition in a mammal associated with aging. Methods of making and using the invention composition are also disclosed.
Abstract: Embodiments of the present invention disclose a composition comprising nicotinamide adenine dinucleotide (NAD+) and optionally a nonsteroidal anti-inflammatory drug (NSAID), wherein the NAD+is in an amount effective for a condition in a mammal associated with aging. Methods of making and using the invention composition are also disclosed.
Abstract: Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.
Abstract: Provided herein are methods and compositions for increasing the expression of a protein, and for treating a subject in need thereof, e.g., a subject with deficient protein expression or a subject having a disease described herein.
Abstract: Provided herein are methods of treating (e.g., inhibiting, modulating, reversing, or reducing the severity of at least one symptom of) a dysbiosis in a subject, the method comprising administering an effective amount of a composition described herein (e.g., a composition comprising polyglucosamine-arginine (PAAG)).
Type:
Application
Filed:
March 16, 2017
Publication date:
March 7, 2019
Inventors:
Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
Abstract: In one aspect, the present invention relates to a new method of treating or osteoarthritis in a mammal in need thereof. In certain embodiments, the method comprises contacting at least one biomimetic proteoglycan with the affected joint of the mammal. The biomimetic proteoglycan comprises a core structure and at least one bristle. The biomimetic proteoglycan resists endogenous enzymatic degradation and integrates with the existing tissue matrix.
Type:
Application
Filed:
November 1, 2018
Publication date:
March 7, 2019
Inventors:
Michele Marcolongo, Katsiaryna Prudnikova, Mary Mulcahey, Evan Phillips